NVIDIA-backed AI drug company Iambic raises $150 million in U.S. IPO

According to Bloomberg, clinical-stage cancer drug development and technology company Iambic Therapeutics Inc., backed by Nvidia Corp., raised $150 million through a U.S. initial public offering (IPO). In a statement released on Wednesday, the company said it sold approximately 9.38 million shares at a price of $16 per share, priced at the midpoint of its previously indicated offering range of $15 to $17.